Heartflow (NASDAQ:HTFL) Insider Campbell Rogers Sells 64,533 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 64,533 shares of the firm’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $25.69, for a total value of $1,657,852.77. Following the sale, the insider owned 78,518 shares in the company, valued at $2,017,127.42. This trade represents a 45.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Campbell Rogers also recently made the following trade(s):

• On Thursday, February 12th, Campbell Rogers sold 65,153 shares of Heartflow stock. The shares were sold at an average price of $24.49, for a total value of $1,595,596.97.

Heartflow Trading Up 3.1%

NASDAQ HTFL opened at $26.82 on Tuesday. The business’s 50-day moving average price is $26.76 and its 200 day moving average price is $30.35. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $41.22. The company has a market capitalization of $2.30 billion and a PE ratio of -14.82.

Institutional Investors Weigh In On Heartflow

Several hedge funds have recently modified their holdings of HTFL. XXEC Inc. lifted its position in Heartflow by 40.5% during the 4th quarter. XXEC Inc. now owns 41,920 shares of the company’s stock worth $1,222,000 after acquiring an additional 12,088 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Heartflow during the fourth quarter valued at approximately $72,000. Invesco Ltd. lifted its position in shares of Heartflow by 463.9% during the fourth quarter. Invesco Ltd. now owns 577,397 shares of the company’s stock worth $16,831,000 after purchasing an additional 475,004 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Heartflow by 282.6% in the fourth quarter. XTX Topco Ltd now owns 43,205 shares of the company’s stock valued at $1,259,000 after purchasing an additional 31,913 shares during the period. Finally, VARCOV Co. acquired a new stake in Heartflow during the 4th quarter valued at $1,657,000.

Analyst Ratings Changes

Several equities research analysts recently issued reports on HTFL shares. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. JPMorgan Chase & Co. lowered their price objective on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Wells Fargo & Company dropped their price target on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Finally, Canaccord Genuity Group increased their price objective on shares of Heartflow from $40.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.